PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
Benzinga We actually see some modest risk around the results given that Phase II data in cUTI were slightly numerically weaker than ceftazidime , and Phase II data in cIAI showed a similar trend versus meropenem. Cubist needs to generate positive data in both ... and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
Seeking Alpha Similar results were obtained when the culture medium contained both daptomycin and a subtherapeutic concentration of vancomycin, clindamycin , tetracycline, or tiamulin. The best results were obtained with tedizolid, which at one quarter the ...
